DME Therapy

Unity reveals data from Phase 1 SAD study of UBX1325

Unity Biotechnology announces improvement in visual acuity sustained through 24 weeks following single dose of UBX1325 in Phase 1 study of patients with advanced vascular eye disease.

Coronavirus induces macrophage-mediated cytokine storm in diabetic patients

A team of investigators from the University of Michigan may have unlocked a potential new recipe for counteracting the impact that COVID-19 has on patients with underlying disease processes such as type 2 diabetes.

Oxurion announces positive results from Part A of phase 2 study evaluating THR-149 for treatment of DME

The company will move the highest dose of THR-149 (0.13mg) into Part B of the study based on favorable safety profile and positive efficacy data.